PET Imaging for Head and Neck Cancer

This trial tests a new PET/CT imaging tool to assess its effectiveness in detecting head and neck cancer. The study aims to determine if this imaging method can accurately identify cancer in individuals with specific types of head and neck cancer, such as those newly diagnosed or with recurrent cancer. Participants will undergo a special imaging scan using 64Cu-DOTA-ECL1i (a radiotracer) before surgery or during their cancer treatment. The trial seeks individuals with head and neck cancer who are either newly diagnosed and scheduled for surgery or have recurring cancer and are beginning a specific type of therapy. As a Phase 2 trial, this research measures the imaging method's effectiveness in an initial, smaller group, offering participants the opportunity to contribute to advancements in cancer detection.

In a previous study, researchers tested 64Cu-DOTA-ECL1i to assess its safety for people. The study found that participants generally tolerated this imaging agent well. Most did not experience serious side effects. Some had minor issues, such as mild nausea or a slight headache, but these resolved quickly.

Although researchers are still studying this imaging agent, its presence in a Phase 2 trial indicates it has passed earlier safety checks. This suggests it may be safe for humans, but researchers continue to gather more information. Participants in the trial will be closely monitored for any side effects.

Researchers are excited about the trial using 64Cu-DOTA-ECL1i PET imaging for head and neck cancer because it provides a new way to visualize and track cancer progression. Unlike the standard treatments, which typically involve surgery, radiation, or chemotherapy, this technique uses a special compound, 64Cu-DOTA-ECL1i, that helps in detailed imaging of cancerous tissues. This could help doctors see how tumors are responding to treatments like anti-PD1 therapy much earlier and with greater precision. This imaging approach could lead to more personalized and effective treatment plans for patients with head and neck cancer.

Research has shown that PET/CT imaging, such as the 64Cu-DOTA-ECL1i PET/CT studied in this trial, outperforms CT scans alone for head and neck squamous cell carcinoma (HNSCC). Participants will be divided into two cohorts: Cohort 1, consisting of newly diagnosed HNSCC patients scheduled for surgical resection, will undergo 64Cu-DOTA-ECL1i PET/CT once before surgery. Cohort 2, consisting of patients with recurrent/metastatic HNSCC who are candidates for first-line anti-PD1 therapy, will undergo 64Cu-DOTA-ECL1i PET imaging twice, once at baseline and once after three therapy cycles. Studies have found that PET/CT more accurately detects cancer recurrence, with high sensitivity (correctly identifying those with the disease) and specificity (correctly identifying those without the disease). In some studies, PET/CT demonstrated 94% accuracy in diagnosing cancer recurrence. Early results suggest that PET scans can effectively track treatment progress and predict outcomes for HNSCC patients, making 64Cu-DOTA-ECL1i an exciting option for more precise cancer imaging.¹²³⁴⁵